Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK104 adjuvant therapy after curative surgery or ablation for high-risk recurrent hepatocellular carcinoma
CTR20221942Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Jan 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in hepatocellular carcinoma (HCC), sponsored by Akeso, Inc.. Started Jan 2023; status: active.
02
Drugs
cadonilimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20221942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221942.